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Abstract
Background: Reduction or inhibition of histone deacetylase 6 (HDAC6) has been shown to rescue memory in
mouse models of Alzheimer’s disease (AD) and is recently being considered a possible therapeutic strategy.
However, the restoring mechanism of HDAC6 inhibition has not been fully understood.
Methods and results: Here, we found that an anti-oxidant protein Peroxdiredoxin1 (Prx1), a substrate of HDAC6,
malfunctions in Aβ treated cells, the brains of 5xFAD AD model mice and AD patients. Malfunctioning Prx1, caused
by reduced Prx1 acetylation levels, was recovered by HDAC6 inhibition. Increasing acetylation levels of Prx1 by
HDAC6 inhibition recovered elevated reactive oxygen species (ROS) levels, elevated Ca2+ levels and impaired
mitochondrial axonal transport, sequentially, even in the presence of Aβ. Prx1 mutant studies on the K197 site for
an acetylation mimic or silencing mutation support the results showing that HDAC6 inhibitor restores Aβ-induced
disruption of ROS, Ca2+ and axonal transport.
Conclusions: Taken together, increasing acetylation of Prx1 by HDAC6 inhibition has several beneficial effects in AD
pathology. Here, we present the novel mechanism by which elevated acetylation of Prx1 rescues mitochondrial
axonal transport impaired by Aβ. Therefore, our results suggest that modulation of Prx1 acetylation by HDAC6
inhibition has great therapeutic potential for AD and has further therapeutic possibilities for other
neurodegenerative diseases as well.
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Background
Alzheimer’s disease (AD) is the most common neurode-
generative disease that leads to cognitive impairment.
The major pathological features of AD are extracellular
accumulation of beta-amyloid (Aβ), called senile plaque,
and intracellular neurofibrillary tangles which are com-
posed of hyperphosphorylated tau [1, 2]. There are sev-
eral well-known cytotoxic effects and molecular changes
of Aβ. Aβ disrupts axonal transport by dysregulating
microtubule stability and affinity between motor or
adaptor proteins and microtubule or cargos [3, 4].
Axonal transport is important for neuronal function and
cell viability [5–7]. Oxidative stress, which is caused by
increased reactive oxygen species (ROS), and excessive
cytosolic Ca2+ are induced by Aβ [1]. ROS oxidize lipids,
proteins and nucleic acids which are essential for normal
cellular function, which leads to increased membrane
permeability to Ca2+, mitochondrial damage and apop-
tosis [8–11]. Excessive Ca2+ is involved in excitotoxicity
which also contributes to neuronal cell death [12, 13]. In
addition, ROS and Ca2+ damage to mitochondrial axonal
transport is mediated by reduced affinity between Miro
and kinesin [14, 15].
One of the molecular changes in AD include increased
levels and activity of histone deacetylase 6 (HDAC6) in
the brains of AD patients [16, 17]. HDAC6 is localized
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in the cytoplasm and deacetylates cytosolic proteins such
as α-tubulin and Peroxiredoxin1 (Prx1) [18–20]. Some
researchers have shown that reducing or inhibiting
HDAC6 in AD model mice resulted in improved mem-
ory [21–23]. In addition, Aβ-induced impairment of
mitochondrial axonal transport was rescued by HDAC6
inhibitor in primary neurons [24]. Even though HDAC6
has great possibility as an AD therapeutic target, the re-
storing mechanisms of HDAC6 inhibition are not fully
understood.
Here we found one possible mechanism which is me-
diated by Prx1. A previous report has shown that in-
creasing Prx1 acetylation elevates its reducing activity
[19]. Since Prx1 is an HDAC6 substrate, increased
HDAC6 activity may cause poor reducing activity of
Prx1. Therefore, we studied whether HDAC6 inhibition
can regulate ROS level through acetylation of Prx1. Fur-
thermore, we tried to elucidate whether restored axonal
transport by HDAC6 inhibitor is mediated by Prx1. To-
gether, we propose that increased acetylation of Prx1 by
HDAC6 inhibition leads to recovery of Aβ-induced path-
ology such as elevation of ROS and Ca2+ and impaired




Neuropathological processing of normal and AD human
brain samples followed the procedures previously estab-
lished for the Boston University Alzheimer’s Disease
Center (BUADC). Entorhinal cortex and hippocampal
regions were used for experiments. Detailed information
of brain tissues is described in Additional file 1. In all
cases where AD was diagnosed at autopsy, AD was
stated as the cause of death. AD subjects had no evi-
dence of other neurological disease based on neuro-
pathological examination. Next of kin provided informed
consent for participation and brain donation. The study
was performed in accordance with principles of human
subject protection in the Declaration of Helsinki. This
study was reviewed by the Boston University School of
Medicine Institutional Review Board and was approved
as exempt because the study involves only tissue col-
lected from post-mortem, and consequently not classi-
fied as human subjects.
Animals and intraperitoneal (i.p.) injection
Six-month-old 5xFAD mice (Tg6799; B6SJL-Tg
(APPSwFlLon, PSEN* M146L*L286V) 6799Vas/J, stock
number 006554, Jackson Labs, Bar Harbor, ME, USA)
overexpressing human amyloid precursor protein 695
with three mutations (Swedish, Florida and London) and
human presenilin 1 with two mutations (M146L and
L286V) under transcriptional control of the murine Thy-
1 promoter and wild type littermate (B6/SJL) were used
for brain tissue analysis after Tubastatin A (TBA) injec-
tion. TBA (100 mg/kg) or saline was administrated daily
by i.p. injection for 4 weeks. Animals were treated and
maintained in accordance with the Animal Care and Use
Guidelines of Seoul National University, Seoul, Korea.
Cell culture and transfection
HT22 cells were cultured in Dulbecco’s modified Eagles
medium (DMEM; HyClone, USA) supplemented with
10% fetal bovine serum (Hyclone, USA) and 1% penicil-
lin/streptomycin (Sigma, USA) at 37 °C under 5% CO2.
Primary neuronal were previously described [25]. Briefly,
primary hippocampal neurons were obtained from the
brain tissue of Sprague–Dawley rat embryos (E18)
(KOATECH, Korea). Brains were incubated in Hank’s
Balanced Salt Solution (HBSS; WelGENE, Korea) with
0.05% trypsin (Gibco, USA) for 20 min at 37 °C. Neu-
rons dissociated in NeuroBasal medium (Gibco, USA)
supplemented with B27 (Gibco, USA) and penicillin/
streptomycin were plated on poly-D-lysine (Sigma, USA)
coated dishes or microfluidic chambers for immunopre-
cipitation or mitochondrial axonal transport analysis, re-
spectively. Half of the culture medium was replaced with
fresh medium every 3 days for plates and every day for
microfluidic chambers. For transfection, constructs were
mixed with Lipofectamine LTX (Invitrogen, USA) in
Opti-MEM (Gibco, USA) for HT22 cells and Lipofecta-
mine 2000 (Invitrogen, USA) in fresh neuronal culture
medium for primary neurons.
DNA constructs, reagents and antibodies
Three Flag-tagged Prx1 constructs – Prx1-WT-Flag,
Prx1-K197Q-Flag and Prx1-K197R-Flag – and another
three non-tagged vectors that express GFP separately –
Prx1-WT, Prx1-K197Q and Prx1-K197R - were used.
Prx1-WT-Flag construct based on pCR3.1 vector was
kindly gifted by Dr. Sang Won Kang (Ewha Womans Uni-
versity, Seoul, Korea). Prx1-K197Q-Flag and Prx1-K197R-
Flag vectors were generated by point mutation from Prx1-
WT-Flag vector using site-directed mutagenesis kit (Enzy-
nomics, Korea) according to manufacturer’s instructions.
Three non-tagged, separately GFP-expressing Prx1 vectors
were constructed from Flag-tagged Prx1 vectors by
BamHI and NotI restriction and insertion into pBI-CMV2
vector (Clontech, USA) which has two identical independ-
ently expressed promoters, one of which expresses
AcGFP. For mitochondrial labeling, pDsRed2-Mito (Clon-
tech, USA) were used. Tubastatin A (TBA) was purchased
from Sigma (USA) and U-chem (Korea). N-acetyl cysteine
(NAC), Trolox (Sigma, USA) and BAPTA-AM (Thermo-
Fisher Scientific, USA), Aβ1–42 peptide (American peptide,
USA and Bachem, Switzerland) were used. Anti-Flag,
acetyl-tubulin and β-actin antibodies were purchased from
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Sigma (USA). Antibodies against Prx1 (CST, USA), 4-
HNE, 8-OHdG (Abcam, UK) and Tom2 (SantaCruz,
USA) were also used. Acetyl-Prx1 antibodies were gener-
ated from chicken using BSA-conjugated synthetic peptide
(Peptron Inc., Korea) with a sequence of SKEYFS-
K(Ac)QK, C-terminal of Prx1. For antibody selection, four
rounds of bio-panning were performed as described previ-
ously using magnetic bead conjugated with BSA-
acetylated Prx1 peptide after removing non-acetylated
Prx1 binders using BSA-non-acetylated Prx1 peptide
(BSA-CGGGSSKEYFSKQK) [26]. Affinity chromatog-
raphy using Protein A agarose beads (Repligen 16 Corp.,
USA) was then used to purify acetyl-Prx1 antibodies
(clone name: R2-31) [27].
Preparation of Aβ
Aβ1–42 peptide (American peptide, USA and Bachem,
Switzerland) was prepared as previously described [25].
In brief, Aβ1–42 peptide was dissolved in 1,1,1,3,3,3-hexa-
fluoro-2-propanol (Sigma, USA) and lyophilized in a
Speedvac (Labconco, USA). The dry peptide was dis-
solved in anhydrous dimethyl sulfoxide (Sigma, USA) at
a final concentration of 1 mM and diluted in DMEM or
cell culture medium. During treating to cells, most of
Aβ consisted predominantly of oligomers and some
monomers [24].
Immunoprecipitation and western blotting
Cells were lysed in 1% Triton X-100 in TBS buffer
(50 mM Tris HCl, 150 mM NaCl, pH 7.4) containing
protease inhibitor cocktail, phenyl-methylsulfonyl fluor-
ide (PMSF) (Sigma, USA) and TBA for HDAC6 inhib-
ition. Flag-tagged Prx1 was immunoprecipitated using
anti-Flag M2 magnetic beads (Sigma, USA) and eluted
by competition with 3xFlag peptide (Sigma, USA) ac-
cording to manufacturer’s instructions. Elutes were
mixed with SDS-PAGE sample buffer, and boiled at 95 °C
for 3 min. For immunoprecipitation of endogenous Prx1,
anti-Prx1 antibodies and protein A/G agarose beads (San-
taCruz, USA) were crosslinked by BS3 (ThermoFisher Sci-
entific, USA) according to manufacturer’s instructions and
then incubated with cell lysates overnight at 4 °C. Precipi-
tates were eluted with SDS-PAGE sample buffer by boiling
at 95 °C for 3 min. Both boiled elutes and equal amounts
of input samples were separated via SDS-PAGE and trans-
ferred to polyvinylidene difluoride (PVDF) membranes.
Membranes were blocked with 5% skim milk (Bioworld,
USA) and probe with antibodies against indicated pro-
teins. Western blotting process has been also described in
a previous report [24].
DCFDA assay
For ROS measurement, cells were treated with 1 μM of
cell-permeant 2′, 7′-dichlorodihydrofluorescein diacetate
(H2DCFDA, mentioned DCFDA in this paper) (Invitro-
gen, USA) in DMEM. After 1 h incubation at 37 °C,
DCFDA was changed with DMEM. Fluorescent signals
were captured using fluorescence microscope (Olympus,
Japan) or CellInsight (Thermo Scientific, USA). Images
obtained from fluorescence microscope were analyzed
using Image J (NIH) and images from CellInsight using its
software.
Fluo-4 assay
For measuring Ca2+ concentration, cells were incubated
with fluo-4 (Invitrogen, USA) for 1 h at 37 °C. After
changing medium to DMEM, fluorescent signals were
captured using fluorescence microscope or CellInsight.
Images obtained from fluorescence microscope were an-
alyzed using Image J (NIH) and from CellInsight using
its software.
Mitochondrial axonal transport analysis
Fabrication of microfluidic chambers and analysis of
mitochondrial axonal transport were described in the
reference [24]. In brief, neurons cultured in microfluidic
chambers were transfected with pDsRed2-Mito at day in
vitro (DIV) 7 or 8 to visualize mitochondria. Prx1 con-
structs, which express AcGFP, were simultaneously
transfected with pDsRed2-Mito. After treatment with in-
dicated compounds, live cells were time-lapse imaged
using Olympus IX81 microscope (Japan) equipped with
a Cool SNAP HQ2 CCD camera (Photometrics, USA),
controlled by MetaMorph Software (Universal Imaging,
USA), for 2 min, with a 1 s interval in an incubating
equipment (Live cell instrument, Korea) which main-
tains 37 °C and 5% CO2. Movies were processed using
MetaMorph. Mitochondrial movement in axons were
analyzed by using Image J installed with multiple kymo-
graph plugins (by J. Rietdorf and A. Seitz).
Immunohistochemistry
Mice were anesthetized with a mixture of Zoletil 50
(Virbac, France) and Rompun (Bayer, USA) solution (3:1
ratio, 1 ml/kg, i.p.) and were transcardially perfused with
phosphate buffered-saline (PBS). The hemisphere of the
brain was dissected and incubated in 4% paraformalde-
hyde (PFA) for 36 h, followed by 30% sucrose for 72 h at
4 °C. Serial 30-μm-thick coronal tissue sections were
made using freezing microtome (Leica, USA). For 4-
HNE and 8-OHdG immunostaining using 3, 3′-diamino-
benzidine (DAB), free-floating sections were incubated
overnight at 4 °C with anti-4-HNE (1:200) and 8-OHdG
(1:400) antibodies diluted in PBS containing 0.3% Triton
X-100, 0.05% bovine serum albumin (BSA) and normal
horse serum. Sections were then treated with 3% H2O2
in PBS for 30 min at room temperature (RT) to quench
the activity of endogenous peroxidase, followed by
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incubation with biotinylated secondary antibodies (1:200;
Vector Laboratories, USA) for 2 h at RT and then with
an avidin-biotin complex (Vector Laboratories, USA) for
1 h at RT. Immunoreactivity was visualized by DAB in
0.05 M Tris-buffered saline (pH 7.6). Finally, sections
were mounted on poly-L-lysine (Sigma, USA) coated
Histobond glass slides (Marienfeld, Germany), air-dried
overnight, serial ethanol dehydrated and coverslipped
with Permount (Fisher Scientific, USA). For fluorescent
staining with anti-acetyl-Prx1 (1:50) and Tom20 (1:200),
sections were incubated overnight at 4 °C with indicated
antibodies diluted in PBS containing 1% Triton X-100
and normal horse serum, followed by incubation with
Alexa Fluor 488 and 594 secondary antibodies (Thermo-
Fisher Scientific, USA) for 1 h at RT. Sections were
washed with PBS every incubation step. For acetyl-Prx1
staining of human brain tissues using DAB, paraffin-
embedded tissue sections were deparaffinized in 55 °C
dry-oven for overnight. Rehydrated and endogenous per-
oxidase quenched tissue sections were incubated with
anti-acetyl-Prx1 antibody (1:100) at 4 °C for overnight
and the rest of procedures were equal to be described
above. The images were acquired using Olympus FSX
100 (Olympus, Japan) or confocal microscope (Carl
Zeiss, Germany) for DAB stained sections or fluorescent
labeling sections, respectively. Image J was used for
quantifying immunoreactivity.
Statistical analysis
Data were analyzed by two-way analysis of variance
(ANOVA) or one-way ANOVA with Bonferroni post-
hoc tests. All data were shown as mean ± SEM.
Results
Acetylation level of Prx1 was decreased in the brains of
AD patients and acetylation of Prx1 is regulated by both
Aβ and HDAC6
Since it was reported that the level and activity of
HDAC6 were increased in AD [16, 17] and Prx1 is one
of substrates of HDAC6 [19], we hypothesized that
acetylation of Prx1 is reduced in AD conditions. First,
we confirmed this hypothesis in human brain samples
(Fig. 1a). As expected, Prx1 acetylation was decreased in
the hippocampus and entorhinal cortex of AD patients
compared to age- and sex-matched normal controls.
This result suggests that upregulated HDAC6 in AD
brains could affect Prx1 acetylation level, and reduced
acetylation level of Prx1 is one of pathological features
of AD brains. To determine whether acetylation of Prx1
is affected by Aβ and HDAC6, we used primary hippo-
campal neurons and HT22 cell line. Endogenous Prx1 in
primary hippocampal neurons showed that acetylation
of Prx1 was reduced by Aβ and recovered by Tubastatin
A (TBA), an HDAC6 inhibitor (Fig. 1b). Similar results
were shown in HT22 cells. In HT22 cells, Aβ decreased
the level of Prx1 acetylation, however, TBA treatment in-
creased the level of Prx1 acetylation even in the presence
of Aβ (Fig. 1c). These results suggest that acetylation of
Prx1 might be one of the crucial factors that modulate
AD pathology and that HDAC6 is involved in these pro-
cesses. To confirm the deacetylation site on Prx1 by
HDAC6, antibodies against acetyl Prx1 at lysine (K) 197
residue were developed and validated by immunoprecip-
itation of a Prx1-WT-Flag and a Prx1-K197R-Flag which
was not acetylated at K197 by substituting K to arginine
(R) (see Additional file 2). To increase acetylation at
K197 of Prx1, the Prx1-WT-Flag transfected HT22 cells
were treated with TBA. It can be confirmed that the
acetyl Prx1 antibody (R2-31) specifically detects acetyl-
ation of Prx1 at K197 because there was no signal in the
Prx1-K197R-Flag, but there was in the Prx1-WT-Flag. In
addition, a stronger signal appeared in the TBA-treated
Prx1-WT-Flag than the non-treated one. These findings
show that acetylation of Prx1 is regulated by both Aβ
and HDAC6.
ROS and Ca2+ are regulated by HDAC6 inhibitor
Since increased acetylation of Prx1 shows more effective
antioxidant activity [19], we tested whether acetylated
Prx1 reduces ROS levels in HT22 cells. To prove it, we
performed a DCFDA assay to measure ROS level in
HT22 cells which were treated with Aβ with or without
TBA. The fluorescence signal of DCFDA was increased
in the Aβ treated group compared to veh. However, in
the Aβ and TBA co-treatment group, the signal was de-
creased compared to the Aβ treated group (Fig. 2a). This
indicates that the HDAC6 inhibitor can reduce the Aβ-
induced elevated ROS level. Several reports showed that
excessive ROS elevates cytoplasmic Ca2+ level through
IP3R or RyR [28–30]. Since Aβ is also known to increase
intracellular Ca2+ level, we measured Ca2+ level using
Fluo-4 assay at the same condition as above. Similar
with ROS level, Ca2+ level was increased by Aβ and res-
cued by TBA in the presence of Aβ (Fig. 2b). In addition,
the results of TBA pretreatment before Aβ were also
showed recovered Aβ-induced ROS and Ca2+ levels by
TBA, which were similar to those of Fig. 2 - posttreat-
ment of TBA (Additional file 3). These results provide
evidence that increased acetylation of Prx1 by HDAC6
inhibitor might regulate ROS as well as Ca2+ levels in
the presence of Aβ.
Aβ-induced ROS regulates intracellular Ca2+ level
To explore whether ROS can regulate Ca2+ level in the
presence of Aβ, we treated trolox and N-acetyl cysteine
(NAC) with Aβ to HT22 cells. Both trolox and NAC,
which is an analog of vitamin E and a precursor to
glutathione, respectively, were ROS inhibitors. 200 μM
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of trolox was enough to suppress ROS when co-treated
with Aβ in HT22 cells (Fig. 3a). Under this condition
(200 μM trolox), where the ROS level is similar to veh
even in the presence of Aβ, the Ca2+ level measured by
Fluo-4 assay was also decreased compared to the Aβ-
treated group (Fig. 3b). NAC, which is a different species
of ROS inhibitor, had similar effects on Aβ-induced ROS
and Ca2+ levels (Additional file 4). These results sug-
gested that ROS could regulate Ca2+ level. In addition,
the reverse direction, in which Ca2+ induces ROS, was
Fig. 1 Acetyl-Prx1 is decreased in AD patients’ brains, and Aβ and HDAC6 inhibitor modulate Prx1 acetylation. a Representative images of acetyl-Prx1
level in human brain samples. Top row shows representative images of age- and sex-matched normal control brains and bottom row shows AD brains.
Scale bar: 100 μm. b Acetylation level of Prx1 in primary hippocampal neurons. Primary hippocampal neurons were treated with Aβ (2 μM, 24 h) and
then co-treated with TBA (1 μM, 3 h). Endogenous Prx1 was immunoprecipitated by anti-Prx1 antibody which was cross-linked to protein A/G coated
agarose beads and probed by indicated antibodies. Left panel shows immunoblot images and right panel shows quantification of acetylation level of
Prx1 which normalized by immunoprecipitated total Prx1 (n = 4, independent experiments). c Acetylation level of Prx1 in HT22 cells. Prx1-WT-Flag
transfected HT22 cells were treated with Aβ (2 μM, 24 h) and then co-treated with TBA (0.5 μM, 3 h). Prx1-Flag was immunoprecipitated by anti-Flag
M2 magnetic beads and probed by indicated antibodies. Left panel shows immunoblot images and right panel shows quantification of acetylation
level of Prx1 which normalized by immunoprecipitated total Prx1 (n = 4, independent experiments). Data are presented as mean ± SEM. *P < 0.05, **P
< 0.01, ***P < 0.001 (two-way ANOVA, Bonferroni post-hoc test)
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examined in the presence of Aβ. HT22 cells were treated
with BAPTA-AM, which is an intracellular Ca2+ chelator,
and Aβ. The BAPTA-AM and Aβ co-treated group showed
lower Ca2+ level, followed by reduced ROS level compared
to Aβ only treated group (Additional file 5). These results
suggest that ROS and Ca2+ regulate each other, and this
leads to a vicious cycle, which accelerates AD pathology.
Recovery of Aβ-induced ROS and Ca2+ elevation by
HDAC6 inhibitor is mediated by acetylation of Prx1
To determine the role of acetylated Prx1 in the recovery
of Aβ-induced ROS and Ca2+, we constructed acetyl
mimic and silencing mutants, K197Q and K197R re-
spectively, by substituting glutamine (Q) or R for K. The
expression level is similar among constructs (Fig. 4a).
Previous study shows that acetyl mimic mutant has
stronger reducing activity compared to WT [19]. Indeed,
acetyl mimic mutant transfected HT22 cells are partially
resistant to Aβ-induced ROS elevation, while acetyl si-
lencing mutant shows results similar to WT by Aβ.
Moreover, even though TBA was co-treated with Aβ in
acetyl silencing mutant transfected HT22 cells, increased
ROS level by Aβ was not restored unlike in WT which
showed restored ROS levels (Fig. 4b). In terms of Ca2+
level, it shows similar patterns to ROS level results
(Fig. 4c). Acetyl mimic mutant groups showed protective
effects against Aβ-induced increased Ca2+ level, and
acetyl silencing mutant groups lost their function com-
pared to WT. It provides evidence that increased Ca2+
by Aβ could be regulated by ROS level which is modulated
Fig. 2 HDAC6 inhibition decreases Aβ-induced ROS and Ca2+. HT22 cells were treated with TBA (0.5 μM, 3 h) after being treated with Aβ (2 μM, 24 h).
a ROS level was measured by DCFDA assay in HT22 cells. Upper panel shows representative DCFDA signals (top row) and bright field images (bottom
row). Lower panel shows quantitative graph of fluorescent intensity (n = 5, independent experiments). b Ca2+ level was measured by Fluo-4 assay in
HT22 cells. Left panel is representative images and right panel is quantification of fluorescent intensity (n = 5, independent experiments). Data are
presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (two-way ANOVA, Bonferroni post-hoc test). Scale bar: 100 μm
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by acetyl Prx1. In addition, there were no additive decreas-
ing effects on ROS and Ca2+ levels under Aβ and TBA co-
treatment compared to Aβ-only treatment in acetyl mimic
mutant groups. This indicates that the ability of TBA to in-
fluence Prx1 activity is dependent on acetylation of K197.
Thus, these data demonstrate that increased acetylation at
K197 of Prx1 by HDAC6 inhibitor contributes to rescue of
ROS level followed by rescue of Ca2+ level in the presence
of Aβ.
HDAC6 inhibitor rescues mitochondrial axonal transport
impaired by Aβ through acetylated Prx1
It is reported that excessive ROS and Ca2+ disrupt
axonal transport [14, 15]. Ca2+, especially, binds to Miro,
which is an adaptor protein that links mitochondria and
kinesin, and inhibits mitochondrial binding to kinesin.
In addition, our previous reports showed that axonal
transport impaired by Aβ is recovered by HDAC6 inhib-
ition [24], which was repeated in Fig. 5a. Thus, we
thought that increased ROS and Ca2+ are possible mech-
anisms by which Aβ disrupts axonal transport, and that
altered acetylation of Prx1 might be involved in these
processes. To determine whether ROS and Ca2+ contrib-
ute to disrupted axonal transport in the presence of Aβ,
we treated Aβ with or without trolox or BAPTA-AM, an
ROS inhibitor or Ca2+ chelator, respectively, to primary
neurons which were transfected pDsRed2-Mito (Fig. 5b
and Additional file 6). Consistent with previous reports,
Fig. 3 Aβ-induced ROS regulates intracellular calcium level. a Aβ-induced ROS was decreased by 200 μM trolox. HT22 cells were pretreated with
indicated concentration of trolox for 1 h before incubation with 2 μM Aβ (24 h). Upper panel is representative images of DCFDA signals (top row)
and bright field (bottom row) to measure ROS level in HT22 cells and lower penal is quantitative graph (n = 4, independent experiments). The re-
sults were shown as mean ± SEM. *P < 0.05, **P < 0.01 (one-way ANOVA, Bonferroni post-hoc test) b Reduction of Aβ-induced ROS level by trolox
can decrease Ca2+ level. HT22 cells were pretreated with 200 μM trolox for 1 h before incubation with 2 μM Aβ (24 h). Left panel is representative
images of Fluo-4 assay to measure Ca2+ level in HT22 cells and right panel is quantitative graph (n = 5, independent experiments). The results
were shown as mean ± SEM. ***P < 0.001 (two-way ANOVA, Bonferroni post-hoc test). Scale bar: 100 μm
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the velocity of mitochondrial axonal transport was de-
creased compared to veh. However, when ROS or Ca2+
was blocked in the presence of Aβ, the velocity of mito-
chondrial axonal transport was recovered. This suggests
that Aβ-induced increased ROS and Ca2+ cause impair-
ment of mitochondrial axonal transport. Mediated by
acetylated Prx1, HDAC6 inhibitor also reduced ROS and
Ca2+ levels elevated by Aβ. Therefore, we determined
whether acetylation of Prx1 also regulates mitochondrial
axonal transport, which is downstream of ROS and Ca2
+, in the presence of Aβ. WT or acetyl mimic (K197Q)
or acetyl silencing (K197R) Prx1 mutant transfected pri-
mary hippocampal neurons were used for observing
mitochondrial axonal transport. Consistent with previ-
ous data, Aβ treated WT and acetyl silencing mutant
group showed decreased velocity of mitochondrial
axonal transport, however, Aβ treated acetyl mimic mu-
tant group still maintained a velocity similar to veh.
When the WT and acetyl silencing mutant groups were
treated with TBA and Aβ, the velocity of mitochondrial
axonal transport was recovered in the WT but not in
the acetyl silencing mutant group (Fig. 5c and Additional
file 7). These results indicate that acetylation of Prx1,
which is modulated by HDAC6 inhibitor, contributes to
the recovery of axonal transport impaired by Aβ. There-
fore, it is suggested that ROS and Ca2+ recovery through
increased acetylation of Prx1 is one of the mechanisms
by which HDAC6 inhibition rescues axonal transport
disrupted by Aβ.
HDAC6 inhibitor rescues oxidative stress and
mitochondrial transport by elevating acetylation of Prx1
in 5xFAD mice
We demonstrated that increased acetylation of Prx1
using HDAC6 inhibitor has potential therapeutic effects
against Aβ by recovering ROS and Ca2+ levels, then re-
covering disrupted mitochondrial axonal transport in
cell culture systems. Next, we investigated whether
HDAC6 inhibitor also shows these therapeutic effects
Fig. 4 Recovery of Aβ-induced ROS and Ca2+ by HDAC6 inhibitor is
mediated by acetylation of Prx1. a Representative immunoblot
showing expression of Prx1-WT or K197Q or K197R-Flag in HT22
cells. Immunoprecipitated exogenous Prx1-Flag showed differential
detecting pattern of acetyl-Prx1 among wild-type and mutants Prx1.
Exogenous Prx1-Flag was probed by anti-Flag antibody. Beta-actin is
loading control. N.C.: Negative Control. b, c Prx1-WT or K197Q or
K197R-Flag transfected HT22 cells were treated with Aβ (2 μM, 24 h)
followed by incubated with TBA (0.5 μM, 3 h). Quantitative graph of
DCFDA assay for ROS measuring (b) and Fluo-4 assay for Ca2+
measuring (c) showed that acetylation of Prx1 regulates ROS and
Ca2+ level in the presence of Aβ, respectively. Data are presented as
mean ± SEM. (b: n = 10, c: n = 7, independent experiments) *P < 0.05,
**P < 0.01, ***P < 0.001, n.s.: non-significant (two-way ANOVA, Bonfer-
roni post-hoc test)
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in vivo using 5xFAD mice, an AD model mice. Six-
month-old 5xFAD mice were injected TBA (100 mg/kg)
for 4 weeks intraperitoneally. Consistent with the data
from cultured cells, acetylation of Prx1 was reduced in
the brains of 5xFAD mice compared to wild type. How-
ever, this reduction was recovered in TBA-injected
5xFAD by showing immunohistochemistry (Fig. 6a).
There are reports showing that, in the brains of AD pa-
tients, some oxidative stress markers were elevated such
as 8-hydroxydeoxyguanosine (8-OHdG), a marker of
oxidative damage to DNA and RNA, and 4-
hydroxynonenal (4-HNE), a product of lipid peroxida-
tion [31–33]. We observed that 4-HNE and 8-OHdG
were also increased in 5xFAD brains by western blot-
ting and immunohistochemistry. However, increased
acetylation of Prx1 by TBA recovered 4-HNE and 8-
OHdG (Fig. 6b,c). These data suggest that reduced
acetylation of Prx1 by Aβ might be involved in in-
creased oxidative stress in 5xFAD. Since we identified
that reduced ROS level recovers mitochondrial axonal
transport in the presence of Aβ, mitochondrial axonal
transport was analyzed with immunohistochemistry
using Tom20, a mitochondrial marker protein, in
mouse brains as previously described [21] (Fig. 6d).
Mitochondrial localization presented by Tom20
immunoreactivity showed more mitochondria
Fig. 5 Aβ-induced ROS disrupts mitochondrial axonal transport by elevating Ca2+ level. a Mitochondrial absolute velocity in axons of primary
hippocampal neurons showing TBA recover impaired mitochondrial axonal transport by Aβ. Mito-dsRed2 transfected primary hippocampal
neurons were treated with Aβ (2 μM, 24 h) followed by incubated with TBA (0.5 μM, 3 h). Data were obtained from 3 independent experiments
(n = 30 cells per group). The results were shown as mean ± SEM. *P < 0.05, ***P < 0.001 (two-way ANOVA, Bonferroni post-hoc test) (b) Disrupted
mitochondrial axonal transport by Aβ is recovered by ROS inhibitor or Ca2+ chelator. Mito-dsRed2 transfected primary hippocampal neurons were
pretreated with trolox (200 μM) or BAPTA (2 μM) for 1 h before incubation with 2 μM Aβ (24 h). Left panel shows kymograph and right panel
shows quantitative graph of mitochondrial absolute velocity. Data were acquired from 4 independent experiments (n = 40 cells per group). The results
were shown as mean ± SEM. **P < 0.01, ***P < 0.001 (two-way ANOVA, Bonferroni post-hoc test) c Acetylation of Prx1 regulate mitochondrial axonal
transport in the presence of Aβ. Prx1-WT or K197Q or K197R and mito-dsRed2 co-transfected primary hippocampal neurons were treated with Aβ
(2 μM, 24 h) followed by incubated with TBA (0.5 μM, 3 h). Left panel shows kymograph and right panel shows quantitative graph of mitochondrial
absolute velocity. Data were obtained from 5 independent experiments (n = 40 cells per group). The results were shown as mean ± SEM. ***P < 0.001,
n.s.: non-significant (one-way ANOVA, Bonferroni post-hoc test), scale bar: 10 μm
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accumulation in the somata of neurons in the CA1
region of 5xFAD compared to wild type. However,
mitochondria were distributed equally from the
somata to the stratum radiatum in CA1 of TBA-
injected 5xFAD, indicating that HDAC6 inhibition
restores mitochondrial axonal transport in vivo. It is
suggested that oxidative stress might be involved in
the disruption of mitochondrial axonal transport in
5xFAD. Taken together, it is supposed that elevating
acetylation of Prx1 by HDAC6 inhibitor plays an im-
portant role in recovering oxidative stress, followed
by recovering mitochondrial axonal transport in vivo.
Thus, regulating acetylation of Prx1 using HDAC6
inhibitor could be a new therapeutic strategy in AD.
Discussion
In the present study, we determine the new role of
acetylation of Prx1 by HDAC6 modulation in AD patho-
genesis related to Aβ. When acetylation of Prx1 at K197
was reduced, mitochondrial axonal transport was dis-
rupted following the elevation of ROS and Ca2+ in the
presence of Aβ. These pathologic features caused by Aβ
were recovered by modulating acetylation of Prx1
through HDAC6 inhibition (Fig. 7). Given that Prx1 is a
substrate of HDAC6, which is increased in level and ac-
tivity in the brains of AD patients [16], reduced acetyl-
ation of Prx1 by Aβ might result from HDAC6
overactivation. Since deacetylated Prx1 has decreased
anti-oxidant activity [19], excessive ROS and Ca2+
Fig. 6 HDAC6 inhibitor rescues oxidative stress and mitochondrial transport by elevating Prx1 acetylation in 5xFAD mice. TBA (100 mg/kg) was i.p. injected
to 6-month-old 5xFAD female mice for 4 weeks. Five mice were used in each group. Cryosectioned brain slice were used in (a, c and d). Brain lysates were
used in (b). a Reduced acetylation of Prx1 is recovered by TBA in 5xFAD mice. Representative images of Ac-Prx1 immunoreactivity in CA1 are shown in left
panel and quantitative graph are in right panel. b, c Oxidative stress is recovered by TBA in 5xFAD mice. Representative immunoblot (left) and quantitative
analysis (right) of 4-HNE are shown in b. Representative DAB stained images (left) against indicated antibodies and quantitative analysis (right) are shown in
c. Immunoreactivity of 4-HNE and 8-OHdG was quantified in cortex and CA1, respectively. d Mitochondrial transport is rescued by TBA in 5xFAD mice.
Anti-Tom20 shows mitochondrial distribution in CA1. Representative images are shown in left panel. Tom20 immunoreactivity in right panel was quantified
as the ratio of intensity in soma to that in stratum radiatum. Data are presented as mean ± SEM (n= 5 per group). *P< 0.05, **P< 0.01, ***P< 0.001 (two-
way ANOVA, Bonferroni post-hoc test), LT: wild-type littermate, 5x: 5xFAD, V: vehicle, TBA: Tubastatin A, scale bar: 10 μm
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caused by Aβ may also be downstream of HDAC6. It is
reported that ROS and excessive Ca2+ impair mitochon-
drial axonal transport [14, 15]. Therefore, disrupted
mitochondrial axonal transport in the presence of Aβ
might be a result of reduced Prx1 acetylation caused by
overactivated HDAC6. Previous studies have shown that
HDAC6 inhibition rescues the Aβ-induced impairment
of mitochondrial axonal transport by increasing acetyl-
ation of α-tubulin, resulting in increased microtubule
stability and the recruitment of motor proteins to micro-
tubules [3, 24, 34, 35]. Alpha-tubulin is a well-known
substrate of HDAC6, and many researches have reported
the relationship between acetylated α-tubulin and axonal
transport [3, 24, 36, 37]. Here, we additively elucidated a
novel mechanism of regulating mitochondrial axonal
transport by HDAC6 inhibition, which modulates acetyl-
ation of Prx1 thereby regulating ROS and Ca2+ levels.
This novel mechanism is more important, because it re-
veals that HDAC6 inhibitor can rescue excessive ROS
and Ca2+ which are other major cellular pathogenic fac-
tors in AD.
In addition, modulation of Prx1 acetylation, not Prx1
itself, is more important for treatment of AD, because
Prx1 is already increased in AD patients’ brains [38, 39].
Although researchers consider that this may be the
result of a cellular protective mechanism [38, 39], oxida-
tive stress still remain in AD brains. Therefore, increas-
ing acetylation of Prx1 is important to elevate anti-
oxidant activity of Prx1. In this study, we demonstrated
that elevating acetylation of Prx1 by HDAC6 inhibition
in AD condition could recovered Aβ-induced oxidative
stress followed by restoring excessive Ca2+ and mito-
chondrial axonal transport. Thus, modulating acetylation
of Prx1 could be one of therapeutic targets for AD.
Several researchers showed that reduction or inhibition
of HDAC6 ameliorated memory impairment in AD mice
model [21–23, 40]. They proposed that the mechanism of
memory rescue works by restoring axonal transport by in-
creasing microtubule stability or recovering autophagy. In
addition, the novel mechanism presented in this study
could explain memory rescue through HDAC6 inhibition.
Well-known pathogenic features of Aβ include elevated
ROS and disrupted Ca2+ homeostasis and axonal transport
[1, 41]. Excessive ROS in AD trigger oxidative stress, which
leads to neuronal dysfunction and cell death by Aβ produc-
tion, lipid peroxidation, enhancement of protein oxidation,
and disruption of gene regulation through DNA oxidation
[8, 31, 42, 43]. Lipid peroxidation causes ion imbalance and
impairs metabolism by weakening cell membranes [44].
Moreover, Torres et al. suggested that the severity of cogni-
tive impairment is directly related to the level of oxidative
stress [45]. Elevated Ca2+ activates several enzymes such as
calcineurin and calpain, which leads to neurite atrophy, dis-
ruption in synaptic plasticity and apoptotic cell death [12,
13, 46, 47]. A report also shows that the onset of cognitive
symptoms in AD is tightly correlated with reduction of Ca2
+-binding proteins [48, 49]. Since neurons have unique po-
larized shapes such as long axons, axonal transport is im-
portant for communication between cell bodies and axon
terminals. Therefore, axonal transport deficit leads to sev-
eral deleterious effects in neurons. Clearance of misfolded
proteins in axons and response to neurotrophic signals or
stress insults require axonal transport [3, 5, 7]. Specifically,
mitochondrial axonal transport is important for supplying
energy to the distal axon to maintain synaptic function [6].
Amyloid precursor protein processing, from which Aβ is
generated, is stimulated by axonal blockade [50]. In
addition, it is reported that excessive ROS and Ca2+ damage
axonal transport of mitochondria and synaptic vesicles [14,
15]. These findings suggest that disrupted ROS, Ca2+
homeostasis and axonal transport, assumed to be early
pathologic events, are crucial for neuronal cell death and
cognitive impairment in AD. Therefore, HDAC6 inhibitor
could recover memory impairment in AD mice models.
Moreover, since disrupted ROS, Ca2+ homeostasis and
axonal transport are common pathologies of neurodegener-
ative diseases [3, 13, 51], it is expected that HDAC6 inhibi-
tor could also have therapeutic effects in other
neurodegenerative diseases.
Fig. 7 Schematic diagram of the role of HDAC6 inhibitor and
acetylation of Prx1 in AD. Increased acetylation of Prx1 by HDAC6
inhibitor rescues impaired mitochondrial axonal transport by
restoring oxidative stress followed by reducing Ca2+ level in AD
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To explore potential use for clinical treatment of HDAC6
inhibitor, we tested both posttreatment and pretreatment of
TBA (Fig. 2 and Additional file 3). The results were similar
in both treatment conditions, in which TBA could recover
Aβ-induced ROS and Ca2+ levels. This indicates that TBA
has both preventive and restorative ability for pathology of
AD. However, we observed a little increasing of Ca2+ in
TBA-alone-pretreatment group unlike in posttreatment
group, although it wasn’t severe increase as much as Aβ-
alone-treated group.
We showed that ROS can regulate mitochondrial
axonal transport mediated by Ca2+. There are reports
that excessive ROS or Ca2+ disrupts mitochondrial
axonal transport [14, 15]. However, how ROS alter mito-
chondrial axonal transport is unclear. Our results show
that when Aβ-induced ROS was blocked by ROS inhibi-
tors or increased acetylation of Prx1 by HDAC6 inhibi-
tor, Ca2+ level decreased, and rescue of mitochondrial
axonal transport followed. It is reported that Ca2+ regu-
lates mitochondrial axonal transport by modulating the
interaction between mitochondria and motor proteins
through Miro, which undergoes conformational changes
as Ca2+ binds to it [15, 52]. Thus, we revealed for the
first time that Ca2+ is a key mediator of ROS-induced
mitochondrial axonal transport deficit.
Although ROS increase Ca2+ level by facilitating Ca2+ re-
lease from the ER or mitochondria, it is well-known that
excessive Ca2+ can also elevate ROS by causing mitochon-
drial dysfunction [13, 31, 53, 54]. Consistent with previous
reports, we showed that reduction of Aβ-induced Ca2+ by
BAPTA decreased ROS levels (Additional file 5). Consider-
ing that Aβ-induced ROS elevate Ca2+, and that Ca2+ also
elevates ROS, a vicious cycle is formed. This cyclic nature
suggests that mitochondrial axonal transport might be very
susceptible to AD.
In this study, we investigated that the elevation of acetyl-
ation of Prx1 by HDAC6 inhibitor partially rescues in-
creased ROS level in the presence of Aβ. Only partial
recovery was achieved possibly due to other redox regula-
tory systems, which remain disrupted by Aβ, such as
superoxide dismutase-2, glutaredoxin 1 and thioredoxin 1
[55]. The precise mechanism needs to be further studied.
Conclusions
We demonstrated a novel mechanism: mediated by re-
storing ROS and Ca2+ level in the presence of Aβ, in-
creased acetylation of Prx1 by HDAC6 inhibitor rescues
impaired mitochondrial axonal transport. This indicates
the new role of Prx1 in regulating mitochondrial axonal
transport which is downstream of HDAC6 and the new
role of HDAC6 in restoring Aβ-induced oxidative stress
and disrupted Ca2+ homeostasis. Therefore, HDAC6 in-
hibition might be a strong therapeutic strategy for AD.
Additional files
Additional file 1: Human brain samples that were used in the study. F:
Female. (PDF 200 kb)
Additional file 2: Anti-acetyl Prx1 (R2-31) antibody specifically detects
acetylated Prx1 at K197. R2-31 antibody specificity was validated by
immunoprecipitation of Flag tagged Prx1-WT or Prx1-K197R using
anti-Flag M2 magnetic beads and probed by R2-31 antibody. Expression
and immunoprecipitation of exogenous Prx1-WT-Flag or Prx1-K197R-Flag
was confirmed by anti-Flag antibody. Immunoblot of Ac-tub in Input
shows TBA works well. N.C.: Negative Control, TBA: Tubastatin A.
(PDF 793 kb)
Additional file 3: Pretreatment of TBA also decreases Aβ-induced ROS
and Ca2+. HT22 cells were pretreated with TBA (0.5 μM) for 1 h before
incubation with Aβ (2 μM, 24 h). a ROS level was measured by DCFDA
assay in HT22 cells. Upper panel is representative images of DCFDA sig-
nals (top row) and bright field images (bottom row) and lower panel is
quantification of fluorescent intensity (n = 6, independent experiments). b
Ca2+ level was measured by Fluo-4 assay in HT22 cells. Left panel is
representative images and right panel is quantification of fluorescent
intensity (n = 4, independent experiments). Data are presented as mean
± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (two-way ANOVA, Bonferroni
post-hoc test). Scale bar: 100 μm. (PDF 3678 kb)
Additional file 4: NAC, an ROS inhibitor, also can regulate Aβ-induced
intracellular calcium level. a Aβ-induced ROS was decreased by 2 mM
NAC. HT22 cells were pretreated with indicated concentration of NAC for
1 h before incubation with 2 μM Aβ (24 h). Upper panel is representative
images of DCFDA signals (top row) and bright field (bottom row) to
measure ROS level in HT22 cells and lower penal is quantitative graph (n
= 5, independent experiments). The results were shown as mean ± SEM.
**P < 0.01 (one-way ANOVA, Bonferroni post-hoc test) b Reduction of
Aβ-induced ROS level by NAC can decrease Ca2+ level. HT22 cells were
pretreated with 2 mM NAC for 1 h before incubation with 2 μM Aβ
(24 h). Left panel is representative images of Fluo-4 assay to measure Ca2
+ level in HT22 cells and right panel is quantitative graph (n = 7, inde-
pendent experiments). The results were shown as mean ± SEM. **P < 0.01,
***P < 0.001 (two-way ANOVA, Bonferroni post-hoc test). Scale bar:
100 μm. (PDF 5662 kb)
Additional file 5: Disrupted Ca2+ homeostasis induced by Aβ affects
ROS level. a Increased Ca2+ level induced by Aβ was reduced by 2 μM
BAPTA. HT22 cells were pretreated with indicated concentration of
BAPTA for 1 h before incubation with 2 μM Aβ (24 h). Left panel is
representative images of Fluo-4 assay to measure Ca2+ level and quantifi-
cation is shown in right panel (n = 6, independent experiments). The re-
sults were shown as mean ± SEM. *P < 0.05, **P < 0.01 (one-way ANOVA,
Bonferroni post-hoc test). b Reduction of Ca2+ by BAPTA can decrease
ROS level in the presence of Aβ. HT22 cells were pretreated with 2 μM
BAPTA for 1 h before incubation with 2 μM Aβ (24 h). In upper panel,
representative DCFDA signals and bright field images were shown in top
row and bottom row, respectively. Quantification graph was shown in
lower panel (n = 6, independent experiments). The results were shown as
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (two-way ANOVA, Bonfer-
roni post-hoc test). Scale bar: 100 μm. (PDF 3018 kb)
Additional file 6: Disrupted mitochondrial axonal transport by Aβ is
recovered by ROS inhibitor or Ca2+ chelator. Representative
mitochondrial movements in axons of primary hippocampal neurons
which are related to Fig. 5b. Scale bar: 10 μm. (MOV 574 kb)
Additional file 7: Acetylation of Prx1 regulate mitochondrial axonal
transport in the presence of Aβ. Representative mitochondrial
movements in axons of primary hippocampal neurons which are related
to Fig. 5c. Scale bar: 10 μm. (MOV 674 kb)
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